Pantoprazole is used to treat stomach and esophageal problems such as acid reflux. It functions by lessening the acid your stomach produces. Heartburn, swallowing issues, and coughing are all alleviated by this medicine. It aids in the repair of esophageal and stomach ulcers and may aid in the prevention of esophageal cancer. Proton pump inhibitors (PPIs) are a class of medications that includes pantoprazole. Pantoprazole is one of the most popular proton pump inhibitors on the market and is used to treat gastroenterological conditions. To prevent future digestive harm, the mode of action regulates the quantity of acid secreted in the stomach. For patients receiving concurrent treatment, the FDA has approved this medication's use in treating erosive esophagitis, pathological hypersecretory diseases like Zollinger-Ellison syndrome, and heartburn problems like GERD. GERD is one of the most common indications, hence the market for Pantoprazole sodium will expand more quickly over the projection period. Furthermore, the availability of several oral medicine kinds tailored to patient needs will promote market growth .
A PPI is called Protonix (pantoprazole sodium). They are potent drugs that stop the stomach's ability to produce acid. They take care of ailments like acid reflux and others. Prilosec and Nexium (esomeprazole) are two other PPIs (omeprazole). Furthermore, the two main drivers driving the growth of the market are rise in prevalence of gastroesophageal reflux disease (GERD) and surge in acceptability of innovative drug delivery technologies. Proton pump inhibitors are the gold standard treatment for GERD.
Increase in prevalence of gastroesophageal reflux disease(GERD)-
The market is growing since GERD is becoming more common. Furthermore, GERD is primarily caused by risk factors such as aging, obesity, delayed stomach emptying, changing smoking habits, and consumption of alcohol, coffee, fatty, & fried foods. For instance, one in six individuals on earth will be 60 or older by 2030, according to figures released by the WHO. By this point, there will be 1.4 billion people over the age of 60, up from 1 billion in 2020. The number of individuals over 60 in the world will double by 2050. (to 2.1 billion). Pantoprazole sodium use is anticipated to rise with the growing elderly population because aging is a significant risk factor for GERD. The classic GERD symptoms may not be present in older people. To ascertain whether symptoms varied according to age groups, Pilotto and colleagues examined GERD symptoms in patients having endoscopic assessments. As a result, it is anticipated that this aspect will boost market growth.
Segment Overview:
By Product Type: Proton-pump inhibitors are a family of drugs that includes pantoprazole. It functions by lessening the production of gastric acid. Pantoprazole is available in different types of products, which include delayed-release tablets, injections, and enteric-coated capsules. One of the most commonly prescribed medications is a proton pump inhibitor (PPI), and over the past few years, ambulatory settings in the U.S. have seen a rise in PPI use. In addition, a lot of businesses are investing significantly in brand promotion. In addition, the American Board of Internal Medicine has taken notice of the pervasive use of PPIs; as a result, the board launched a campaign to encourage their proper use. Furthermore, market development is anticipated to be boosted by the rise in healthcare costs, alterations in lifestyle, and expanding geographic reach of the players in this region.
By Application Type: It is mainly used to treat gastroenterology and hematology diseases. The two main drivers driving the growth of the pantoprazole sodium market are the rising prevalence of gastroesophageal reflux disease (GERD) and the expanding acceptability of innovative drug delivery technologies. Proton pump inhibitors are the gold standard treatment for GERD. Moreover, it is used to both avoid and treat stomach ulcers. The rare disease known as Zollinger-Ellison syndrome, which is brought on by a tumor in the pancreas or gut, is occasionally treated with pantoprazole.
By Region: North America presently dominates the pantoprazole sodium market, and it is predicted that during the forecast period, it will continue to do so without experiencing any significant changes. Due to a change in people's lifestyles towards unhealthy ones, the prevalence of GERD (gastroesophageal reflux disease) is increasing in the U.S., Canada, and Mexico. The pantoprazole sodium market is growing as a result of the increase in transition from prescription to over-the-counter medications. However, the pantoprazole sodium market development may be hampered by the rise in prevalence of generic products and their associated side effects.
Competitive analysis and profiles of the major players in the pantoprazole sodium market, such as
Hubei Weisen Pharmaceutical, Lee Pharma Ltd., Liaoning Nirvana Pharmaceutical, Luye Pharma Group, Mreeo Pharmaceutical, Nirvana Pharmaceutical, Mreeo Pharmaceutical, Shandong Renhetang Pharmaceutical, and Teva Pharmaceutical Industries Limited. Major players have adopted product launch and acquisition as key developmental strategies to improve the product portfolio of the pantoprazole sodium market.
Key Market Segments
- By Product Type
- Delayed-Release Tablets
- Injection
- Enteric-Coated Capsules
- By Application
- Gastroenterology
- Hepatology (Liver, Pancreatic, Gall Bladder)
- By Region
- North America
- Europe
- France
- Germany
- Italy
- Spain
- UK
- Russia
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Thailand
- Malaysia
- Indonesia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- South Africa
- Saudi Arabia
- UAE
- Argentina
- Rest of LAMEA
Key Market Players
- Pfizer Inc.
- takeda gmbh
- Dr Reddy’s Laboratories
- Shandong Renhetang Pharmaceutical
- Teva Pharmaceutical Industries Limited
- Liaoning Nirvana Pharmaceutical
- Luye Pharma Group
- Hubei Weisen Pharmaceutical
- Mreeo Pharmaceutical
- Lee Pharma Ltd.